Abstract
Although risk-based monitoring (RBM) high-level definitions and processes are similar across the pharmaceutical industry, the practical implementation, organizational structures, naming of documents and processes, system capabilities, etc. can be different from company to company. Through an alliance-level relationship, Janssen, PAREXEL, and IQVIA have gained experience and developed best practices with RBM operational deployment, particularly regarding RBM setup and collaboration between sponsor and contract research organization (CRO). As part of the operational strategy, Janssen, PAREXEL, and IQVIA jointly developed an outsourcing manual to consistently guide trial delivery. The outsourcing manual recently adopted policies and implementation guidelines for RBM. Clarity around roles and responsibilities as well as a good understanding of system capabilities and data flows, especially where there are shared systems between the sponsor and CRO, are found to be key success factors. Besides possible organizational changes and the development of mutual processes and system capabilities, the human element is not to be underestimated. Managing the changes in processes and change in mind set within both the sponsor and CRO organization is crucial to successful implementation of RBM, and our experience in this regard forms the basis of this paper.
Similar content being viewed by others
References
TransCelerate. RBM Methodology 2014_RBM informational modules 1-4_9JAN2015.http://www.transceleratebiopharmainc.com/wp-content/uploads/2016/01/8D_RBM-Informational-Modules-1-4_9Jan2015.pptx. Accessed November 2016.
ICH Harmonised Tripartite Guideline, Guideline for Good Clinical Practice E6(R2). ICH web site. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2__Step_4.pdf. Accessed December 2016.
European Medicines Agency. Reflection paper on risk based quality management in clinical trials. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500155491.pdf. Accessed October 2014.
US Food and Drug Administration. Guidance for industry oversight of clinical investigations: a risk-based approach to monitoring. www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm269919.pdf. Accessed October 2014.
Clinical Trials Transformation Initiative Quality by Design Project. CTTI recommendations: quality by design. http://www.ctti-clinicaltrials.org/files/QbD_toolkit/CTTI%20Quality%20by%20Design%20Recommendations_FINAL_1JUN15.pdf. Accessed June 15, 2015.
Trancelerate RBM Technology White Paper—part 2- FINAL 16DEC2015, REV 09FEB2016. http://www.transceleratebiopharmainc.com/wp-content/uploads/2015/04/TransCelerate-RBM-Technology-White-Paper-part-2-FINAL-16Dec2015-REV-09Feb2016.docx. Accessed November 2016.
Meeker-O’Connell A, Glessner C, Behm M, et al. Enhancing clinical evidence by proactively building quality into clinical trials. Clin Trials. 2016;13(4):439–444.
Gough J, Math M, Wilson B, et al. Defining a central monitoring capability: sharing the experience of TransCelerate BioPharma’s approach, part 2. Therapeutic Innovation & Regulatory Science. 2016;50(1):8–14.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wolfs, M., Bambic, A., Lange, B.Sd. et al. Risk-Based Monitoring: Key Conditions in Collaboration Between Contract Research Organization and Sponsor. Ther Innov Regul Sci 53, 512–518 (2019). https://doi.org/10.1177/2168479018793883
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479018793883